Background. The measurement of blood pressure (BP) at home by patients with hypertension is increasingly used to assess and monitor BP. Evidence for its effectiveness in improving BP control is mixed.
A primary care pragmatic cluster randomized trial of the use of home blood pressure monitoring on blood pressure levels in hypertensive patients with above target blood pressure 
Introduction
The measurement of blood pressure (BP) at home by patients with hypertension is being increasingly used by physicians and patients to assess and monitor BP control. 1 If it is effective in increasing both awareness of BP levels and adherence to medication, then this approach fits nicely into the concepts of self-care and chronic disease management and may result in more effective treatment of hypertension. In 2004, Cappuccio et al. 2 published a meta-analysis of clinical trials on home BP monitoring. The review included studies that had been conducted in hospital-based clinics, general practice and community settings up to the end of 2002. The interventions all involved home BP monitoring but varied as to how the information was used by the physician to make treatment decisions. The review included studies with different measurements of outcome: office measurement by the physician, measurement by a trained technician and ambulatory blood pressure monitoring (ABPM). They did not report the results by the type of outcome assessment.
They concluded that BP was better controlled and BP targets were more likely to be achieved when patients monitored their BP at home. Since Cappuccio et al. published the meta-analysis in 2004, other randomized controlled trials have looked at home BP monitoring as an intervention. Halme et al. 3 compared home monitoring for a week at baseline and then at 2, 4 and 6 months and found an improvement in BP control. This approach does not reflect the usual way patients use home monitoring devices. The home BP measurement at 6 months was the outcome assessed.
Verberk et al. 4 compared treatment decisions based on home BP readings compared with office BP readings. They found equivalent BP control but at a lower cost for home BP monitoring when BP outcome was assessed by office visit or home BP. However, when assessed by ABPM, the BP was actually slightly higher in the self-monitoring group.
Staessen et al. 5 compared adjustment of antihypertensive treatment based on home BP instead of office BP. They found that when decisions were based on home BP, there was less intensive drug treatment and marginally lower costs but also less BP control, with no differences in general well-being or left ventricular mass.
Green et al. 6 conducted a three-arm study comparing (i) usual care; (ii) home BP monitoring and training about BP on a website and (iii) home monitoring, web-based training and web communication with a pharmacist about medication management. The group allocated to pharmacist care had better BP control based on BP assessed at 12 months by a trained technician. Den Hond et al. 7 compared the management of high BP using office BP compared to home BP and found no difference in the level of BP control.
Parati et al. 8 used telemonitoring and teletransmission of home BP monitoring results in a trial that compared this to usual care. They found better control based on ABPM in the telemonitoring group.
The evidence to date is mixed. The questions that studies have tried to answer differ; the studies have not all been done in primary care where most hypertension management occurs; the interventions have differed; the outcome measures have not been consistent, and the results have differed.
The rationale for conducting our study was based on the belief that in the family practice environment, hypertensive patients with above target BP would improve their BP control if they monitored their BP at home. We wanted to conduct a study that did nothing to interfere with the process of BP management except the addition of home BP monitoring. We hypothesize that treatment decisions by physicians are not based solely on the home BP readings, but neither is this information ignored. Rather we hypothesized, family physicians base their treatment decisions on their own measurements in the office and take the home BP readings into account. To test this, we conducted a pragmatic cluster randomized trial where the physicians' management was not dictated in any way; the patient simply presented the results of home BP monitoring to the physicians at each visit as would happen in ordinary practice. We asked them to treat to target BP according to the Canadian guidelines but did not dictate which medications they could use nor how often they saw the patient. A cluster design was used to avoid physicians having patients in both arms of the trial, which may have lead to contamination of management in control group patients; if physicians intensified their management due to the presence of home BP measurements in intervention group patients, this may have lead to a general increase in intensity of management in all their patients.
Methods

Study population
The study population consisted of patients of family physicians in southeastern Ontario, Canada; recruitment and follow-up occurred between 2002 and 2005. Physicians' practices were located in the city of Kingston, population 150 000, or in surrounding smaller towns. Physicians had to be in full-time general practice, had to care for patients with hypertension and had to have patients with hypertension who were not at target BP. The physicians were members of an informal practice-based research network that was created for this study and were characterized mainly by their common willingness to be involved in recruiting for primary care research. To be eligible, patients had to be aged >18 years, with a diagnosis of hypertension, on antihypertensive medications and not at target BP (defined as BP measurements recorded on the chart during the last three visits to their family doctor being >140 mmHg systolic and/or >90 mmHg diastolic). Patients were ineligible if they had a diagnosis of secondary hypertension, a physical impairment that prevented them from using a home BP device or terminal illness. Existence of other comorbid conditions did not exclude patients from the study.
Baseline data
Baseline data were collected prior to randomization. Consenting patients underwent 24-hour ABPM. Final determination of eligibility for the study was based on the mean awake BPs on ABPM, which was required to be >135 mmHg systolic and/or >85 mmHg diastolic. Data were collected on age; sex; duration of hypertension and risk factors such as diabetes, smoking, body mass index and waist circumference and any assessment of compliance. A baseline assessment of Family Practice-an international journal BP was also completed using the BpTRUä automated device that is designed to automatically take five measurements of BP while the patient is sitting alone in the doctor's office. This device has been suggested as a potential alternative to ABPM when ABPM cost or availability is an issue. 9 
Randomization
Cluster randomization was conducted. After all the physician's eligible consenting patients had baseline data collected, the physician and all his participating patients were randomized as a cluster to either the intervention arm or the control arm of the study. The research assistant (RA) collecting the baseline data contacted the project coordinator to determine random assignment; the project coordinator held the randomization schedule but was not aware of which physician was about to be randomized. This process provided masking of the randomization. Randomization was stratified by number of patients in the cluster (1-10 or >10) to avoid the higher clusters being all randomized to the same study arm by chance. After randomization, the RA contacted the patients by telephone informing them of the arm of the study to which they had been assigned and asking them to make an appointment within the next 2 weeks to see their family doctor.
Intervention group
Patients in the intervention group were provided with a validated A&D UA-767 home BP monitoring device for their use and which they could keep after the study. They were instructed by the RA in the proper use of the device and how to interpret the results. They could use the device as often as they wished but as a minimum we asked that they measure their BP weekly during the study period (1 year), record those measurements in a booklet provided and bring the booklet to the family physician each time they went for an office visit.
Intervention physicians were asked to review the results of patients' home BP measurements whenever the patient visited for a BP check. They were informed that the home BP target was <135/85 mmHg and to take the home BP results into account when making decisions about BP management.
Control group
Patients in the control group were asked to carry on with their BP care as usual. They were asked not to purchase or use a home BP measurement device during the course of the study.
Physicians in both the control and the intervention groups were asked to treat their patients to a target of office BP <140/90 mmHg. They were provided with a copy of the Canadian hypertension guidelines as developed by the Canadian Hypertension Education Program but were not told explicitly which drugs to use or how often to see the patient. The intervention physicians were also asked to review the patient's booklet of recorded home BP measurements at each visit.
Outcome measures
Outcomes were measured at 6 and 12 months after randomization. Outcomes included the full, awake and sleep results on 24-hour ABPM using the A&D TM-2430 device, as well as the mean of the five automatic measurements on the BpTRU device. These measurements were conducted by the RA and the devices were attached and removed in the physician's office. For purposes of a priori sample size calculation, the awake ABPM at 12 months was set as the primary outcome. To detect a difference of 3 mmHg between the groups, using an alpha of 0.05 and beta of 0.1 (power = 90%) and accounting for the cluster randomization using an intra-class correlation of 0.03, we calculated we would need 284 in each group.
Analysis
Missing systolic and diastolic BP data from ABPM and BpTRU were imputed using a propensity score multiple imputation technique, 10 the Markov chain Monte Carlo method. Imputation was carried out separately for different sexes and intervention groups.
Using 10 imputed datasets, multilevel modelling was applied to analyse each of the BP measurements at each follow-up visit (Month 6 or 12) to compare the intervention with control taking into account the cluster (physician) samples of patients. Results from these 10 imputed datasets were combined and summarized in tables.
With the same 10 imputed datasets, multilevel modelling was extended to include the baseline BP measurement as a covariate and combine the longitudinal data (two follow-up visits), so that the effect of using home BP device can be assessed taking into account the baseline and time variations. Results were combined and summarized in tables. The decision to analyse and present data by sex was made a priori.
All the imputations, multilevel modelling and the combining of the results of analyses were carried out using SAS Version 9.1 package. The statistician analysing the data was blinded to group assignment. The study was reviewed and approved by the Research Ethics Board of Queen's University in Kingston, Ontario, Canada.
Results
A total of 55 family physicians and 552 patients were recruited for the study: 24 physicians (285 patients) were randomly allocated to the intervention group and 31 physicians (267 patients) were randomly allocated to usual care. The CONSORT diagram (Fig. 1) provides details on cluster size and lost to follow-up. All patients, even the 88 who were lost to follow-up, were included in the analysis by using imputed data for ABPM and BpTRU values as described in the Methods section. Table 1 provides information on the baseline characteristics of the intervention and control groups. The two groups were similar at baseline. The systolic BP recently measured in the physicians' offices and recorded on the chart was higher in the intervention group than in the control group. However, there was no difference in the mean ambulatory BPs between the groups at baseline. Tables 2-6 summarize the results.
Systolic BP
For the primary outcome, the awake BP on ABPM, there was no statistical difference in the home monitoring group compared to the usual care group at 6 months (141.9 versus 144.4 mmHg; P = 0.086) or 12 months (141.1 versus 142.8 mmHg; P = 0.314) for systolic BP. Similarly, there was no difference in systolic BP when the asleep measures on ABPM or the full 24-hour ABPM were compared between the two groups. However, when the outcome was measured using BpTRU, there was a statistically significant difference between intervention and control at 6 months (132.2 versus 138.7 mmHg; P = 0.002), although the difference was no longer present at 12 months (132.8 versus 136.1 mmHg; P = 0.143). When men and women were analysed separately, men in the intervention group had statistically lower systolic BP at 6-month follow-up on awake ABPM, full 24-hour ABPM and BpTRU (see Table 3 ) but these differences were not maintained at 12 months. For women, there was no difference between intervention and control using any form of outcome measurement of systolic BP at 6 or 12 months (see Table 4 ).
FIGURE 1 CONSORT diagram for cluster randomized trials
Family Practice-an international journal Diastolic BP For the primary outcome, the awake BP on ABPM, there was no statistical difference in the home monitoring group compared to the usual care group at 6 months (79.3 versus 81.0 mmHg; P = 0.078) or 12 months (78.7 versus 79.4 mmHg; P = 0.398) for diastolic BP. However, when BP was measured by the full 24-hour ABPM and by the BpTRU device, there was a statistically significant difference between intervention and control groups at both 6 and 12 months with the intervention group having lower BP (see Table 2 ). When men and women were analysed separately, men in the intervention group had statistically lower diastolic BP at 6-month follow-up on awake ABPM, full 24-hour ABPM and BpTRU (see Table 3 ) and these significant differences were maintained at 12 months for full 24-hour ABPM and BpTRU. For women, there was no difference between intervention and control using any form of outcome measurement of diastolic BP at 6 or 12 months (see Table 4 ). When the BP outcomes were adjusted for both the cluster effect and the baseline BPs, there remained no difference between intervention and control groups in women on any of the BP measurement modalities, systolic or diastolic. In men, when the results were cluster and baseline adjusted, the systolic awake ABPM measurements and systolic BpTRU measurements were significantly lower in the intervention group at 6 months but not at 12 months. For diastolic, the intervention group had significantly lower readings on BpTRU at both 6 and 12 months but no other measurement modalities showed any difference.
The intervention effect (intervention-control difference) was consistent (in the same direction) across the two follow-up visits (6 and 12 months). There was no group Â time interaction. The full 24-hour ABPM Family Practice-an international journal was the only BP measurement that showed a consistent mean BP decrease from 6 to 12 months within each group (P < 0.04); however, this could have been a chance finding due to multiple testing. The baseline BP measurement was highly related to the subsequent follow-up measurements (P < 0.0001).
Discussion
Other studies 4,5 using ABPM as the outcome measure have not shown lower BPs in hypertensive patients using home BP monitoring. Our study, while showing consistently lower BPs in the home monitoring group compared to the usual care group, only showed this convincingly and with statistical significance in men, and even then, it was primarily at 6-month follow-up with the effect becoming less by 12 months. Cappuccio The sex difference in the effectiveness of home BP monitoring has been noted previously by Soghikian et al. 11 As in our study, the differential effect favoured men.
We used a pragmatic approach. Our experience suggests that, except in clinical trials, patients use home BP monitors to keep an eye on their BP and to take the results of their monitoring to their physician when they visit. Furthermore, our experience suggested that while physicians review the results of patients monitoring and take those into consideration, their management decision is likely based on many different objective and subjective pieces of information. In an attempt to duplicate this, we tried not to change usual practice in the intervention group except for the fact that the patients had, and were asked to use, home BP monitors. Apart from the provision of standard guidelines, we gave no instruction regarding frequency of visits, which medication to use or how and when to adjust medication dosage. We asked only that they attempt to treat to target and that they review the patients monitoring record when they came in for a visit. We did not involve other health care professionals, and we did not ask the patients to adjust their own medications, and the physician was free to use whatever pieces of data they had (office BP; patient's stress level; knowledge of the patient and his/her social, psychological and medical conditions). We did not exclude people with various cardiovascular diseases or diabetes. Hence, this was a very heterogeneous population typical of primary care. The differences were not large; however, we did find a small and persistent improvement in diastolic BP with home monitoring in men. This may not be a large enough difference to warrant a recommendation that all patients with hypertension purchase home BP monitors.
There are circumstances in which a home monitor may provide benefit such as white coat hypertension, if BP is not controlled despite several medications, and in patients who are particularly adept at electronic devices or who like to measure and monitor their own care. Risks of home BP monitoring include the added anxiety in those who become fearful when their BP is not at target.
The decision to utilize a home BP monitor should be a decision made jointly by the patient and the care provider. Home BP monitoring is unlikely to overcome lack of attention to lifestyle, salt intake and medication compliance by the patient or lack of careful monitoring and medication adjustment by the physician.
Limitations
The pragmatic nature of this study is both its weakness and its strength. The heterogeneity of the population, the lack of blinding and the lack of tight control of the intervention, which are often features of a pragmatic trial, can cause issues with internal validity. However, it is this same heterogeneity and real-world application of the intervention that enhances the generalizability or external validity of the results. Another potential issue with this study is the relatively large number of participants who were lost to follow-up and the need to use imputed data in those cases. However, the imputations were done with great care and using an accepted statistical process.
Conclusions
In clinical practice, home BP monitoring may provide a small and lasting effect on diastolic BP control in men. There are a number of other, perhaps more compelling, reasons why a physician might recommend to a hypertensive patient that he/she starts monitoring his/her BP at home. We need to better understand the complexities of the problem of BP control to further clarify the role of self-monitoring.
